Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients

PLoS Pathogens

Volumn 11, Issue 1, 2015, Pages 1-21

  Yue, Ling ^a   Pfafferott, Katja J ^b   Baalwa, Joshua ^c   Conrod, Karen ^b   Dong, Catherine C ^a   Chui, Cecilia ^b   Rong, Rong ^a   Claiborne, Daniel T ^a   Prince, Jessica L ^a   Tang, Jianming ^c   Ribeiro, Ruy M ^d   Cormier, Emmanuel ^e   Hahn, Beatrice H ^f   Perelson, Alan S ^d   Shaw, George M ^f   Karita, Etienne ^g   Gilmour, Jill ^e   Goepfert, Paul ^c   Derdeyn, Cynthia A ^a,h   Allen, Susan A ^h   Borrow, Persephone ^b   Hunter, Eric ^a,h   more..

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c and Clinical Center   (United States)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Project San Francisco   (Rwanda)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1;

ALLELE; ANTIBODY RESPONSE; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; T LYMPHOCYTE; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS TRANSMISSION; ADULT; AMINO ACID SEQUENCE; GENETICS; HEK293 CELL LINE; HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE EVASION; IMMUNOLOGY; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PHYLOGENY; PROGNOSIS; REPRODUCTIVE FITNESS; TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AMINO ACID SEQUENCE; EPITOPES, T-LYMPHOCYTE; EVOLUTION, MOLECULAR; FEMALE; GENETIC FITNESS; HEK293 CELLS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; PROGNOSIS; T-LYMPHOCYTES; VIRAL LOAD; VIRUS REPLICATION;

EID: 84923846505     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004565     Document Type: Article

References (109)

1. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD, (1994) Long-term HIV-1 infection without immunologic progression. AIDS 8: 1123–1128.
2. Lobritz MA, Lassen KG, Arts EJ, (2011) HIV-1 replicative fitness in elite controllers. Current opinion in HIV and AIDS 6: 214–220.
3. Mellors JW, Kingsley LA, Rinaldo CR, JrTodd JA, Hoo BS, et al. (1995) Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of internal medicine 122: 573–579.
4. Cao Y, Qin L, Zhang L, Safrit J, Ho DD, (1995) Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. The New England journal of medicine 332: 201–208.
5. Deeks SG, Walker BD, (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406–416.
6. Munoz A, Kirby AJ, He YD, Margolick JB, Visscher BR, et al. (1995) Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Association 8: 496–505.
7. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W, (1993) The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7: 1159–1166.
8. Baker BM, Block BL, Rothchild AC, Walker BD, (2009) Elite control of HIV infection: implications for vaccine design. Expert opinion on biological therapy 9: 55–69.
9. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, et al. (2009) Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. The Journal of infectious diseases 200: 1714–1723.
10. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, et al. (2005) HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 41: 1053–1056.
11. McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, et al. (2012) Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Human molecular genetics 21: 4334–4347.
12. O'Connell KA, Bailey JR, Blankson JN, (2009) Elucidating the elite: mechanisms of control in HIV-1 infection. Trends in pharmacological sciences 30: 631–637.
13. Streeck H, Nixon DF, (2010) T cell immunity in acute HIV-1 infection. The Journal of infectious diseases 202 Suppl 2: S302–308.
14. Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, et al. (1994) The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 204: 223–233.
15. Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, et al. (2008) Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS pathogens 4: e1000033.
16. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, et al. (2009) Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med 206: 909–921.
17. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, et al. (2008) Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. The Journal of experimental medicine 205: 1009–1017.
18. Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, et al. (2012) Role of Transmitted Gag CTL Polymorphisms in Defining Replicative Capacity and Early HIV-1 Pathogenesis. PLoS pathogens 8: e1003041.
19. Tang J, Malhotra R, Song W, Brill I, Hu L, et al. (2010) Human leukocyte antigens and HIV type 1 viral load in early and chronic infection: predominance of evolving relationships. PloS one 5: e9629.
20. Wright JK, Naidoo VL, Brumme ZL, Prince JL, Claiborne DT, et al. (2012) Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. Journal of virology 86: 3193–3199.
21. Yue L, Prentice HA, Farmer P, Song W, He D, et al. (2013) Cumulative Impact of Host and Viral Factors on HIV-1 Viral-Load Control during Early Infection. Journal of virology 87: 708–715.
22. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551–1557.
23. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944–947.
24. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, et al. (2009) Common genetic variation and the control of HIV-1 in humans. PLoS Genet 5: e1000791.
25. Tang J, Tang S, Lobashevsky E, Zulu I, Aldrovandi G, et al. (2004) HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partners. AIDS Research and Human Retroviruses 20: 19–25.
26. Goulder PJ, Watkins DI, (2008) Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nature reviews Immunology 8: 619–630.
27. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, et al. (2010) Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. Journal of virology 84: 9879–9888.
28. Matthews PC, Adland E, Listgarten J, Leslie A, Mkhwanazi N, et al. (2011) HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703. Journal of immunology 186: 5675–5686.
29. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nature medicine 13: 46–53.
30. Shacklett BL, (2010) Immune responses to HIV and SIV in mucosal tissues: ‘location, location, location’. Current opinion in HIV and AIDS 5: 128–134.
31. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature medicine 3: 212–217.
32. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282–289.
33. Goulder PJ, Watkins DI, (2004) HIV and SIV CTL escape: implications for vaccine design. Nature reviews Immunology 4: 630–640.
34. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature medicine 3: 205–211.
35. Jones NA, Wei X, Flower DR, Wong M, Michor F, et al. (2004) Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. The Journal of experimental medicine 200: 1243–1256.
36. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, et al. (2010) Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. Journal of virology 84: 11937–11949.
37. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, et al. (2009) HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. Journal of virology 83: 2743–2755.
38. Bailey JR, Williams TM, Siliciano RF, Blankson JN, (2006) Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. The Journal of experimental medicine 203: 1357–1369.
39. Alizon S, von Wyl V, Stadler T, Kouyos RD, Yerly S, et al. (2010) Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS pathogens 6: e1001123.
40. Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, et al. (2010) HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 24: 941–945.
41. Hollingsworth TD, Laeyendecker O, Shirreff G, Donnelly CA, Serwadda D, et al. (2010) HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog 6: e1000876.
42. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, et al. (2000) Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. The Journal of infectious diseases 181: 872–880.
43. Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, et al. (2011) Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. Journal of virology 85: 3996–4006.
44. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, et al. (2008) Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. Journal of virology 82: 8422–8430.
45. Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, et al. (2009) HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. Journal of virology 83: 140–149.
46. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, et al. (2010) Impaired replication capacity of acute/early viruses in persons who become HIV controllers. Journal of virology 84: 7581–7591.
47. Lassen KG, Lobritz MA, Bailey JR, Johnston S, Nguyen S, et al. (2009) Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS pathogens 5: e1000377.
48. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, et al. (2007) Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. Journal of virology 81: 2508–2518.
49. Boeras DI, Hraber PT, Hurlston M, Evans-Strickfaden T, Bhattacharya T, et al. (2011) Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proceedings of the National Academy of Sciences of the United States of America 108: E1156–1163.
50. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019–2022.
51. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, et al. (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS pathogens 5: e1000274.
52. Rousseau CM, Birditt BA, McKay AR, Stoddard JN, Lee TC, et al. (2006) Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. Journal of virological methods 136: 118–125.
53. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. The Journal of experimental medicine 206: 1273–1289.
54. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. The Journal of experimental medicine 206: 1253–1272.
55. Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, et al. (2012) Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS pathogens 8: e1002721.
56. Baalwa J, Wang S, Parrish NF, Decker JM, Keele BF, et al. (2013) Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology 436: 33–48.
57. Boutwell CL, Carlson JM, Lin TH, Seese A, Power KA, et al. (2013) Frequent and Variable Cytotoxic-T-Lymphocyte Escape-associated Fitness Costs in the Human Immunodeficiency Virus Type 1 Subtype B Gag Proteins. Journal of virology
58. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, et al. (2007) Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. Journal of virology 81: 12608–12618.
59. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, et al. (2007) Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. Journal of virology 81: 8346–8351.
60. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. (1999) Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. The Journal of experimental medicine 189: 991–998.
61. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857–860.
62. Liu MK, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, et al. (2013) Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest 123: 380–393.
63. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, et al. (2011) Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 9: 208.
64. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, et al. (2010) Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. Journal of virology 84: 10543–10557.
65. Ferrari G, Korber B, Goonetilleke N, Liu MK, Turnbull EL, et al. (2011) Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS pathogens 7: e1001273.
66. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358–8367.
67. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905.
68. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB, (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. Journal of virology 68: 6103–6110.
69. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. Journal of virology 68: 4650–4655.
70. Turnbull EL, Wong M, Wang S, Wei X, Jones NA, et al. (2009) Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. Journal of immunology 182: 7131–7145.
71. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871–1879.
72. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, et al. (2009) Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. Journal of virology 83: 329–335.
73. Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, et al. (2007) Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. Journal of immunology 179: 3133–3143.
74. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852–856.
75. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781–4789.
76. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, et al. (2008) Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009–1021.
77. Ribeiro-dos-Santos P, Turnbull EL, Monteiro M, Legrand A, Conrod K, et al. (2012) Chronic HIV infection affects the expression of the 2 transcription factors required for CD8 T-cell differentiation into cytolytic effectors. Blood 119: 4928–4938.
78. Apps R, Qi Y, Carlson JM, Chen HY, Gao XJ, et al. (2013) Influence of HLA-C Expression Level on HIV Control. Science 340: 87–91.
79. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. Journal of virology 77: 2081–2092.
80. Ganusov VV, Goonetilleke N, Liu MK, Ferrari G, Shaw GM, et al. (2011) Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. Journal of virology 85: 10518–10528.
81. van Deutekom HW, Wijnker G, de Boer RJ, (2013) The rate of immune escape vanishes when multiple immune responses control an HIV infection. Journal of immunology 191: 3277–3286.
82. Mudd PA, Ericsen AJ, Burwitz BJ, Wilson NA, O'Connor DH, et al. (2012) Escape from CD8(+) T cell responses in Mamu-B*00801(+) macaques differentiates progressors from elite controllers. Journal of immunology 188: 3364–3370.
83. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, et al. (2009) Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. Journal of virology 83: 1845–1855.
84. Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, et al. (2008) Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. Journal of virology 82: 7700–7710.
85. Frleta D, Ochoa CE, Kramer HB, Khan SA, Stacey AR, et al. (2012) HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest 122: 4685–4697.
86. Overbaugh J, Morris L, (2012) The Antibody Response against HIV-1. Cold Spring Harbor perspectives in medicine 2: a007039.
87. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, et al. (1996) Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. The Journal of infectious diseases 173: 60–67.
88. Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J, (1998) Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12: 1591–1600.
89. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, Zolla-Pazner S, (1999) A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. The Journal of infectious diseases 179: 1365–1374.
90. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, et al. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. The Journal of infectious diseases 197: 563–571.
91. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, et al. (2009) Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. Journal of virology 83: 188–199.
92. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, et al. (2009) Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23: 897–906.
93. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, et al. (2009) Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. Journal of virology 83: 662–672.
94. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, et al. (2013) Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth. PLoS Pathog 9: e1003173.
95. Overbaugh J, Rudensey LM, (1992) Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. Journal of virology 66: 5937–5948.
96. Chackerian B, Rudensey LM, Overbaugh J, (1997) Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. Journal of virology 71: 7719–7727.
97. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America 100: 4144–4149.
98. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307–312.
99. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, et al. (2006) Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. Journal of virology 80: 5211–5218.
100. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H, (2008) Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. Journal of virology 82: 7932–7941.
101. Moore PL, Gray ES, Morris L, (2009) Specificity of the autologous neutralizing antibody response. Current opinion in HIV and AIDS 4: 358–363.
102. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, et al. (2009) Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS pathogens 5: e1000594.
103. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, et al. (2007) Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. Journal of virology 81: 4886–4891.
104. Lynch RM, Rong R, Boliar S, Sethi A, Li B, et al. (2011) The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol 85: 905–915.
105. Trask SA, Derdeyn CA, Fideli U, Chen Y, Meleth S, et al. (2002) Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. Journal of virology 76: 397–405.
106. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America 105: 7552–7557.
107. Roederer M, Koup RA, (2003) Optimized determination of T cell epitope responses. Journal of immunological methods 274: 221–228.
108. Pantaleo G, Soudeyns H, Demarest JF, Vaccarezza M, Graziosi C, et al. (1997) Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proceedings of the National Academy of Sciences of the United States of America 94: 9848–9853.
109. Poss M, Gosink J, Thomas E, Kreiss JK, Ndinya-Achola J, et al. (1997) Phylogenetic evaluation of Kenyan HIV type 1 isolates. AIDS Res Hum Retroviruses 13: 493–499.